Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06676488 · ClinicalTrials.gov registry record · NA
A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome
A NA study of Irritable Bowel Syndrome (IBS) and Circadian Misalignment, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06676488: Recruiting NA study of Irritable Bowel Syndrome (IBS) and Circadian Misalignment, sponsored by Medical University of South Carolina.
NCT06676488 is a NA study of Irritable Bowel Syndrome (IBS) and Circadian Misalignment that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 30 participants, below the 1,183-participant average among 5 other Irritable Bowel Syndrome (IBS) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06676488, a NA study of Irritable Bowel Syndrome (IBS) and Circadian Misalignment, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to assess whether morning bright light therapy (BLT) using a wearable device called a Re-Timer could potentially improve Irritable Bowel Syndrome (IBS) symptoms and decrease intestinal permeability (leaky gut). Morning bright light therapy will be administrated through a safe-wearable glasses device called a Re-Timer. The Re-Timer glasses are lightweight and deliver blue-green light at 500nm, mimicking exposure to natural light.
Primary Outcome
In Aim 1a, we predict 2 weeks of morning BLT in IBS subjects with CM will improve IBS-symptom severity based on the IBS Severity Scoring Scale as compared to the control (wear the Re-Timer™ glasses without light therapy).
Conditions Studied
Interventions
- DEVICE Re-Timer glasses
- DEVICE Placebo Device
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What NCT06676488 shows while recruiting
NCT06676488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,183-participant average among 5 other Irritable Bowel Syndrome (IBS) trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Irritable Bowel Syndrome (IBS) appearing as the primary indexed condition, and to 2 interventions - of which Re-Timer glasses is the first listed.
NCT06676488 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT06676488 about?
NCT06676488 is a clinical study titled "A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome". The purpose of this research study is to assess whether morning bright light therapy (BLT) using a wearable device called a Re-Timer could potentially improve Irritable Bowel Syndrome (IBS) symptoms and decrease intestinal permeability (leaky gut). Morning bright light therapy will be administrated ...
What is the current status of trial NCT06676488?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-06-11. Estimated completion is 2026-03-31.
What conditions does trial NCT06676488 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome (IBS), Circadian Misalignment.
What interventions are being tested in trial NCT06676488?
The interventions under investigation include: Re-Timer glasses (DEVICE), Placebo Device (DEVICE).
Who is sponsoring clinical trial NCT06676488?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06676488 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome (IBS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
RECRUITING · NA
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
-
Prospective Observational Study of Naturopathic Approaches to IBS
RECRUITING
-
Diet and Motility in IBS
RECRUITING
-
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI